Astria (ATXS) CEO reports stock and option cancellation in BioCryst deal
Rhea-AI Filing Summary
Astria Therapeutics CEO Jill C. Milne reported the cancellation of her Astria equity holdings in connection with the company’s merger with BioCryst Pharmaceuticals. On January 23, 2026, she disposed of 4,377 shares of common stock, leaving her with no directly held Astria common shares.
On the same date, two blocks of Astria stock options were reported as disposed of: a 195,000-share option with a $6.51 exercise price and a 761,000-share option with a $6.41 exercise price, with zero options remaining after the transactions. Under the merger terms, each Astria share outstanding at the effective time (other than excluded shares) was converted into the right to receive 0.59 BioCryst common shares plus $8.55 in cash per share, subject to taxes. In-the-money Astria options became fully vested and were canceled in exchange for a cash payment based on a $13.00 reference price.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 195,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 761,000 | $0.00 | -- |
| Disposition | Common Stock | 4,377 | $0.00 | -- |
Footnotes (1)
- This number has been adjusted to reflect the 1-for-10 reverse stock split the Issuer effected on December 28, 2018 and the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes. At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
